Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study

Rb Lipton, David William Dodick, Ju Adelman, Rg Kaniecki, Se Lener, Jd White, Ac Nelsen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD & Nelsen AC. Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009. London. ISSN 0333-1024 Two identical randomized, placebo-controlled, crossover studies were conducted to evaluate consistency of response to sumatriptan-naproxen sodium 85-500 mg (S-NS) over four attacks in adults with migraine. Patients were instructed to treat within 1 h of pain onset while pain was mild. Co-primary end-points were pain-free response at 2 h (2hPF) and 24-h sustained pain-free response (24hSPF) calculated as percentages of all attacks. In Study 1, 570 patients treated 1693 attacks with S-NS and 424 with placebo. In Study 2, 565 patients treated 1678 attacks with S-NS and 422 with placebo. Compared with placebo, S-NS conferred higher 2hPF rates (Study 1: S-NS 52%, placebo 25%; Study 2: S-NS 50%, placebo 20%; both P < 0.001) and higher 24hSPF rates (Study 1: S-NS 37%, placebo 17%; Study 2: S-NS 34%, placebo 12%; both P < 0.001). 2hPF was reported in at least two of the first three S-NS-treated attacks in 55.0% of patients in Study 1 and 52.1% of patients in Study 2. 24hSPF was reported in at least two of the first three S-NS-treated attacks in 35.7% of patients in Study 1 and 32.6% of patients in Study 2. The incidences of any adverse event and of specific adverse events were low and generally similar between S-NS and placebo.

Original languageEnglish (US)
Pages (from-to)826-836
Number of pages11
JournalCephalalgia
Volume29
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Naproxen
Cross-Over Studies
Placebos
sumatriptan-naproxen
Pain
Migraine Disorders
Headache

Keywords

  • Acupuncture
  • Clinical trial
  • Headache
  • Migraine

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study. / Lipton, Rb; Dodick, David William; Adelman, Ju; Kaniecki, Rg; Lener, Se; White, Jd; Nelsen, Ac.

In: Cephalalgia, Vol. 29, No. 8, 08.2009, p. 826-836.

Research output: Contribution to journalArticle

Lipton, Rb ; Dodick, David William ; Adelman, Ju ; Kaniecki, Rg ; Lener, Se ; White, Jd ; Nelsen, Ac. / Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study. In: Cephalalgia. 2009 ; Vol. 29, No. 8. pp. 826-836.
@article{ce8cabe06c6f4bd5a17c2264d313987f,
title = "Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study",
abstract = "Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD & Nelsen AC. Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009. London. ISSN 0333-1024 Two identical randomized, placebo-controlled, crossover studies were conducted to evaluate consistency of response to sumatriptan-naproxen sodium 85-500 mg (S-NS) over four attacks in adults with migraine. Patients were instructed to treat within 1 h of pain onset while pain was mild. Co-primary end-points were pain-free response at 2 h (2hPF) and 24-h sustained pain-free response (24hSPF) calculated as percentages of all attacks. In Study 1, 570 patients treated 1693 attacks with S-NS and 424 with placebo. In Study 2, 565 patients treated 1678 attacks with S-NS and 422 with placebo. Compared with placebo, S-NS conferred higher 2hPF rates (Study 1: S-NS 52{\%}, placebo 25{\%}; Study 2: S-NS 50{\%}, placebo 20{\%}; both P < 0.001) and higher 24hSPF rates (Study 1: S-NS 37{\%}, placebo 17{\%}; Study 2: S-NS 34{\%}, placebo 12{\%}; both P < 0.001). 2hPF was reported in at least two of the first three S-NS-treated attacks in 55.0{\%} of patients in Study 1 and 52.1{\%} of patients in Study 2. 24hSPF was reported in at least two of the first three S-NS-treated attacks in 35.7{\%} of patients in Study 1 and 32.6{\%} of patients in Study 2. The incidences of any adverse event and of specific adverse events were low and generally similar between S-NS and placebo.",
keywords = "Acupuncture, Clinical trial, Headache, Migraine",
author = "Rb Lipton and Dodick, {David William} and Ju Adelman and Rg Kaniecki and Se Lener and Jd White and Ac Nelsen",
year = "2009",
month = "8",
doi = "10.1111/j.1468-2982.2008.01806.x",
language = "English (US)",
volume = "29",
pages = "826--836",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study

AU - Lipton, Rb

AU - Dodick, David William

AU - Adelman, Ju

AU - Kaniecki, Rg

AU - Lener, Se

AU - White, Jd

AU - Nelsen, Ac

PY - 2009/8

Y1 - 2009/8

N2 - Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD & Nelsen AC. Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009. London. ISSN 0333-1024 Two identical randomized, placebo-controlled, crossover studies were conducted to evaluate consistency of response to sumatriptan-naproxen sodium 85-500 mg (S-NS) over four attacks in adults with migraine. Patients were instructed to treat within 1 h of pain onset while pain was mild. Co-primary end-points were pain-free response at 2 h (2hPF) and 24-h sustained pain-free response (24hSPF) calculated as percentages of all attacks. In Study 1, 570 patients treated 1693 attacks with S-NS and 424 with placebo. In Study 2, 565 patients treated 1678 attacks with S-NS and 422 with placebo. Compared with placebo, S-NS conferred higher 2hPF rates (Study 1: S-NS 52%, placebo 25%; Study 2: S-NS 50%, placebo 20%; both P < 0.001) and higher 24hSPF rates (Study 1: S-NS 37%, placebo 17%; Study 2: S-NS 34%, placebo 12%; both P < 0.001). 2hPF was reported in at least two of the first three S-NS-treated attacks in 55.0% of patients in Study 1 and 52.1% of patients in Study 2. 24hSPF was reported in at least two of the first three S-NS-treated attacks in 35.7% of patients in Study 1 and 32.6% of patients in Study 2. The incidences of any adverse event and of specific adverse events were low and generally similar between S-NS and placebo.

AB - Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD & Nelsen AC. Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009. London. ISSN 0333-1024 Two identical randomized, placebo-controlled, crossover studies were conducted to evaluate consistency of response to sumatriptan-naproxen sodium 85-500 mg (S-NS) over four attacks in adults with migraine. Patients were instructed to treat within 1 h of pain onset while pain was mild. Co-primary end-points were pain-free response at 2 h (2hPF) and 24-h sustained pain-free response (24hSPF) calculated as percentages of all attacks. In Study 1, 570 patients treated 1693 attacks with S-NS and 424 with placebo. In Study 2, 565 patients treated 1678 attacks with S-NS and 422 with placebo. Compared with placebo, S-NS conferred higher 2hPF rates (Study 1: S-NS 52%, placebo 25%; Study 2: S-NS 50%, placebo 20%; both P < 0.001) and higher 24hSPF rates (Study 1: S-NS 37%, placebo 17%; Study 2: S-NS 34%, placebo 12%; both P < 0.001). 2hPF was reported in at least two of the first three S-NS-treated attacks in 55.0% of patients in Study 1 and 52.1% of patients in Study 2. 24hSPF was reported in at least two of the first three S-NS-treated attacks in 35.7% of patients in Study 1 and 32.6% of patients in Study 2. The incidences of any adverse event and of specific adverse events were low and generally similar between S-NS and placebo.

KW - Acupuncture

KW - Clinical trial

KW - Headache

KW - Migraine

UR - http://www.scopus.com/inward/record.url?scp=67650330264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650330264&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2008.01806.x

DO - 10.1111/j.1468-2982.2008.01806.x

M3 - Article

VL - 29

SP - 826

EP - 836

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 8

ER -